New Obesity Drug Delivers Up to 25% Weight Loss in Trial

Retatrutide, a triple-hormone drug that simultaneously targets GLP-1, GIP, and glucagon receptors, has produced weight loss of up to 25% in clinical trials — making it the most powerful obesity treatment yet reported. That outpaces existing GLP-1 drugs like semaglutide, and the results are already drawing comparisons to a step-change in metabolic medicine.